pulmonary hypertension who group 3

Pulmonary arterial hypertension (PAH) in WHO Group 3 typically results from increased pulmonary artery pressure due to left-sided heart disease, pulmonary disorders, or hypoxia. Patients in this category may experience an increased cardiac workload, which can potentially lead to heart failure.

The causes of PAH in WHO Group 3 are varied, with conditions ranging from mild chronic obstructive pulmonary disease (COPD) to severe interstitial lung diseases contributing to this condition. For instance, in COPD patients, chronic airway obstruction reduces the efficiency of pulmonary gas exchange, leading to increased pulmonary vascular resistance and, ultimately, PAH. Interstitial lung disease patients experience damage to the tissue between alveoli and capillaries, which similarly results in increased pulmonary vascular resistance. Additionally, rare conditions such as sleep apnea syndrome or pulmonary tuberculosis can also cause PAH.

Regular monitoring of pulmonary artery pressure and timely medical consultation are essential for individuals with pulmonary diseases or those experiencing hypoxia. Upon a diagnosis of PAH, it is imperative to follow a standardized treatment regimen under a physician's supervision and to avoid self-medicating. Moreover, adopting a healthier lifestyle, including smoking cessation, a balanced diet, and regular exercise, can aid in managing the progression of the disease.